Use of sevelamer in chronic kidney disease: beyond phosphorus control
Nefrología (English Edition), 2015 Sevelamer is a non-calcium phosphate binder used in advanced chronic kidney disease (CKD) and in dialysis for hyperphosphataemia control. Several experimental, observational studies and clinical trials have shown that sevelamer has pleiotropic effects ...
Laura Rodríguez-Osorio +6 more
doaj +1 more source
Vascular Calcification in Patients with Chronic Kidney Disease: Types, Clinical Impact and Pathogenesis [PDF]
, 2013 Vascular calcification plays a major role in cardiovascular disease, which is one of the main causes of mortality in chronic kidney disease patients. Vascular calcification is determined by prevalent traditional and uraemia-related (non-traditional) risk
Cabezas-Rodríguez, Iván +5 more
core
Do higher dialysate calcium concentrations increase vascular stiffness in haemodialysis patients as measured by aortic pulse wave velocity? [PDF]
, 2013 Background: Haemodialysis patients have an increased prevalence of hypertension and risk of cardiovascular mortality and stroke. Higher dialysate calcium concentrations have been reported to cause both an acute and chronic increase in arterial ...
Charitaki, E, Davenport, A
core +1 more source
Phosphate in Physiological and Pathological Mineralization: Important yet Often Unheeded
MedComm, Volume 6, Issue 7, July 2025.Phosphate serves as a building block for physiological mineralization, and as a signaling molecule that regulates the activity of mineralizing cells. The disturbance in these processes could induce a series of pathological mineralization, with abnormal mineralization of hard tissues and ectopic mineralization of soft tissues being the most ...
Wen Qin +8 more
wiley +1 more source
Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism [PDF]
, 2013 Background: Secondary hyperparathyroidism (SHPT) is one of the common complications in dialysis patients, and is associated with increased risk of vascular calcification.
Akagi, Shigeru +8 more
core +1 more source
Polymeric Anti‐Antibiotic Microparticles to Prevent Antibiotic Resistance Evolution
Small, Volume 21, Issue 21, May 26, 2025.This study introduces sevelamer (SEV) microparticles as a repurposed adjuvant therapy to combat antimicrobial resistance. SEV microparticles effectively capture vancomycin (VAN) and daptomycin (DAP), preventing these last‐resort antibiotics from driving resistance.
Roya Koshani +8 more
wiley +1 more source
International Journal of Nephrology, 2018 Background. Hyperphosphatemia in chronic kidney disease (CKD) patients is often treated with calcium carbonate (CaCO3) despite the fact that CaCO3 is associated with increased calcium load and potentially increased cardiovascular risk.
B. L. Goh, A. Soraya, A. Goh, K. L. Ang
doaj +1 more source
Safety and Phosphate‐Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers
Clinical and Translational Science, Volume 18, Issue 1, January 2025.ABSTRACT Despite the widespread use of currently available serum phosphate management options, elevated serum phosphate is common in patients with end‐stage kidney disease on dialysis. Characteristics of currently available phosphate binders that lead to poor patient experiences such as large drug volume size of required daily medication (e.g., many ...
Pablo E. Pergola +7 more
wiley +1 more source
Sevelamer, a phosphate-binding resin with beneficial effect in diabetic kidney disease; a modern paradigm shift [PDF]
, 2014 The proportion of individuals diagnosed with diabetes mellitus is increasing throughout the world, which sequentially drives upward the global frequency of diabetic kidney disease (1, 2). Diabetes is a costly and deadly disease.
Baradaran, Azar. +4 more
core
The role of the gastrointestinal tract in phosphate homeostasis in health and chronic kidney disease. [PDF]
, 2013 For a number of years, there has been increasing interest in the concept of directly targeting intestinal phosphate transport to control hyperphosphatemia in chronic kidney disease. However, progress has been slow due to the paucity of information on the
Debnam, ES, Marks, J, Unwin, RJ
core +1 more source